Literature DB >> 10189185

Cytotoxic T-lymphocyte responses to HIV-1 reverse transcriptase (review).

L Menéndez-Arias1, A Mas, E Domingo.   

Abstract

Cytotoxic T lymphocytes (CTL) play an important role in the control of human immunodeficiency virus (HIV) infection. CTL responses have been demonstrated for most of the HIV gene products, predominantly gag, pol, and env-encoded proteins, and also for the regulatory proteins Nef, Tat, Vif, or Rev. The HIV-1 reverse transcriptase (RT), which derives from expression of the pol gene, is an important target of cellular immune responses in infected individuals. More than 40 different peptides containing RT-specific CTL epitopes have been identified. The most conserved and frequently detected are located in the 'fingers' and 'palm' subdomains of the enzyme, but other epitopes have been found in the 'thumb' and 'connection' subdomains as well as in the RNase H domain. Studies on the sequence variability and functional role of amino acids forming CTL epitopes are relevant for addressing important questions relative to viral escape from immmune control and the future design of anti-AIDS vaccines.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10189185     DOI: 10.1089/vim.1998.11.167

Source DB:  PubMed          Journal:  Viral Immunol        ISSN: 0882-8245            Impact factor:   2.257


  7 in total

1.  Differences in Evolution of HIV-1 Subtype C Reverse Transcriptase Between Children and Adults Likely Explained by Maturity of Cytotoxic T-Lymphocyte Responses.

Authors:  Shanmugam Saravanan; Selvamurthi Gomathi; Bagavathi Kausalya; Jayaseelan Boobalan; Kailapuri G Murugavel; Pachamuthu Balakrishnan; Sarvode N Mothi; Sunil S Solomon; Nagalingeswaran Kumarasamy; Poongulali Selvamuthu; Suniti Solomon; Davey M Smith
Journal:  AIDS Res Hum Retroviruses       Date:  2015-04-28       Impact factor: 2.205

2.  Sequence analysis of the polymerase domain of HIV-1 reverse transcriptase in naive and zidovudine-treated individuals reveals a higher polymorphism in alpha-helices as compared with beta-strands.

Authors:  L Medrano; L Menéndez-Arias; R De Jorge; M L Villahermosa; G Contreras; L Pérez-Alvarez; A Moya; R Nájera
Journal:  Virus Genes       Date:  1999       Impact factor: 2.332

3.  Vaccine-induced immune responses in rodents and nonhuman primates by use of a humanized human immunodeficiency virus type 1 pol gene.

Authors:  Danilo R Casimiro; Aimin Tang; Helen C Perry; Romnie S Long; Minchun Chen; Gwendolyn J Heidecker; Mary-Ellen Davies; Daniel C Freed; Natasha V Persaud; Sheri Dubey; Jeffrey G Smith; Diane Havlir; Douglas Richman; Michael A Chastain; Adam J Simon; Tong-Ming Fu; Emilio A Emini; John W Shiver
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

4.  Rapid progressing allele HLA-B35 Px restricted anti-HIV-1 CD8+ T cells recognize vestigial CTL epitopes.

Authors:  Christian B Willberg; Keith E Garrison; R Brad Jones; Duncan A Meiklejohn; Gerald Spotts; Teri J Liegler; Mario A Ostrowski; Annika C Karlsson; Frederick M Hecht; Douglas F Nixon
Journal:  PLoS One       Date:  2010-04-21       Impact factor: 3.240

5.  HLA-associated clinical progression correlates with epitope reversion rates in early human immunodeficiency virus infection.

Authors:  A Duda; L Lee-Turner; J Fox; N Robinson; S Dustan; S Kaye; H Fryer; M Carrington; M McClure; A R McLean; S Fidler; J Weber; R E Phillips; A J Frater
Journal:  J Virol       Date:  2008-11-19       Impact factor: 5.103

6.  Conservation of functional domains and limited heterogeneity of HIV-1 reverse transcriptase gene following vertical transmission.

Authors:  Vasudha Sundaravaradan; Tobias Hahn; Nafees Ahmad
Journal:  Retrovirology       Date:  2005-05-26       Impact factor: 4.602

7.  Mapping the drivers of within-host pathogen evolution using massive data sets.

Authors:  Duncan S Palmer; Isaac Turner; Sarah Fidler; John Frater; Dominique Goedhals; Philip Goulder; Kuan-Hsiang Gary Huang; Annette Oxenius; Rodney Phillips; Roger Shapiro; Cloete van Vuuren; Angela R McLean; Gil McVean
Journal:  Nat Commun       Date:  2019-07-09       Impact factor: 14.919

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.